The blood-brain barrier in psychosis.

[1]  Jennifer M. Coughlin,et al.  Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia , 2018, Molecular Psychiatry.

[2]  I. Galea,et al.  The blood-brain barrier in systemic inflammation , 2017, Brain, Behavior, and Immunity.

[3]  O. Howes,et al.  Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization , 2017, Translational Psychiatry.

[4]  B. Engelhardt,et al.  The movers and shapers in immune privilege of the CNS , 2017, Nature Immunology.

[5]  A. Meyer-Lindenberg,et al.  Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis , 2017, Schizophrenia bulletin.

[6]  R. Woltjer,et al.  The Translational Significance of the Neurovascular Unit* , 2016, The Journal of Biological Chemistry.

[7]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[8]  Alan S. Verkman,et al.  Spatial model of convective solute transport in brain extracellular space does not support a “glymphatic” mechanism , 2016, The Journal of general physiology.

[9]  M. Webster,et al.  Transcriptome sequencing of the choroid plexus in schizophrenia , 2016, Translational Psychiatry.

[10]  Bernhard Bogerts,et al.  Morphometric analysis of the cerebral expression of ATP-binding cassette transporter protein ABCB1 in chronic schizophrenia: Circumscribed deficits in the habenula , 2016, Schizophrenia Research.

[11]  S. Hladky,et al.  Fluid and ion transfer across the blood–brain and blood–cerebrospinal fluid barriers; a comparative account of mechanisms and roles , 2016, Fluids and Barriers of the CNS.

[12]  R. Murray,et al.  Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses , 2016, Psychological Medicine.

[13]  M. Cuénod,et al.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? , 2016, Schizophrenia Research.

[14]  W. Muller.  Transendothelial migration: unifying principles from the endothelial perspective , 2016, Immunological reviews.

[15]  R. Murray,et al.  Adversity in childhood linked to elevated striatal dopamine function in adulthood , 2016, Schizophrenia Research.

[16]  Peter C M van Zijl,et al.  Abnormal Grey Matter Arteriolar Cerebral Blood Volume in Schizophrenia Measured With 3D Inflow-Based Vascular-Space-Occupancy MRI at 7T , 2016, Schizophrenia bulletin.

[17]  S. Summerfield,et al.  Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[18]  G. Pell,et al.  Glutamate-Mediated Blood–Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery , 2016, The Journal of Neuroscience.

[19]  R. Ferreira,et al.  Cellular response of the blood-brain barrier to injury: Potential biomarkers and therapeutic targets for brain regeneration , 2016, Neurobiology of Disease.

[20]  A. Egerton,et al.  Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. , 2016, JAMA psychiatry.

[21]  V. Haroutunian,et al.  Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons? , 2016, Molecular Psychiatry.

[22]  Shafiqur Rahman,et al.  Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  E. Ling,et al.  The Choroid Plexus in Healthy and Diseased Brain , 2016, Journal of neuropathology and experimental neurology.

[24]  B. Engelhardt,et al.  Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. , 2016, Biochimica et biophysica acta.

[25]  M. Schroeter,et al.  Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia—A Meta-Regression Analysis , 2016, Front. Cell. Neurosci..

[26]  M. Neri,et al.  Early Loss of Blood-Brain Barrier Integrity Precedes NOX2 Elevation in the Prefrontal Cortex of an Animal Model of Psychosis , 2016, Molecular Neurobiology.

[27]  J. Kieswich,et al.  Estrogen protects the blood–brain barrier from inflammation-induced disruption and increased lymphocyte trafficking , 2016, Brain, Behavior, and Immunity.

[28]  B. Jansson,et al.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy , 2016, Molecular Psychiatry.

[29]  R. Keep,et al.  Junctional proteins of the blood-brain barrier: New insights into function and dysfunction , 2016, Tissue barriers.

[30]  P. McGuire,et al.  Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications , 2015, Psychopharmacology.

[31]  P. Pasinelli,et al.  Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders , 2015, Brain Research.

[32]  Atsushi B. Tsuji,et al.  In-vivo imaging of blood–brain barrier permeability using positron emission tomography with 2-amino-[3-11C]isobutyric acid , 2015, Nuclear medicine communications.

[33]  Fanglin Guan,et al.  Common variants in SLC1A2 and schizophrenia: Association and cognitive function in patients with schizophrenia and healthy individuals , 2015, Schizophrenia Research.

[34]  S. Heringa,et al.  Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review , 2015, Schizophrenia Research.

[35]  S. Kapur,et al.  Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses , 2015, European Neuropsychopharmacology.

[36]  R. Daneman,et al.  Formation and maintenance of the BBB , 2015, Mechanisms of Development.

[37]  M. Campbell,et al.  The dynamic blood–brain barrier , 2015, The FEBS journal.

[38]  Alessandra Bertoldo,et al.  Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study. , 2015, The American journal of psychiatry.

[39]  L. Tebartz van Elst,et al.  Immunological findings in psychotic syndromes: a tertiary care hospital's CSF sample of 180 patients , 2015, Front. Hum. Neurosci..

[40]  A. Bar-Or,et al.  Neuroinflammation: Ways in Which the Immune System Affects the Brain , 2015, Neurotherapeutics.

[41]  S. Kushner,et al.  Pre-eclampsia and first-onset postpartum psychiatric episodes: a Danish population-based cohort study , 2015, Psychological Medicine.

[42]  E. Aronica,et al.  Status epilepticus, blood–brain barrier disruption, inflammation, and epileptogenesis , 2015, Epilepsy & Behavior.

[43]  Maria K. Lehtinen,et al.  Development and functions of the choroid plexus–cerebrospinal fluid system , 2015, Nature Reviews Neuroscience.

[44]  R. Murray,et al.  Does tobacco use cause psychosis? Systematic review and meta-analysis , 2015, The lancet. Psychiatry.

[45]  B. Engelhardt,et al.  Brain barriers: Crosstalk between complex tight junctions and adherens junctions , 2015, The Journal of cell biology.

[46]  F. Nielsen,et al.  Detection and quantification of microRNA in cerebral microdialysate , 2015, Journal of Translational Medicine.

[47]  F. Marques,et al.  The choroid plexus is modulated by various peripheral stimuli: implications to diseases of the central nervous system , 2015, Front. Cell. Neurosci..

[48]  H. Lerche,et al.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature , 2015, Clinical Pharmacokinetics.

[49]  R. Murray,et al.  Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis , 2015, Schizophrenia bulletin.

[50]  A. Grace,et al.  Translating the MAM model of psychosis to humans , 2015, Trends in Neurosciences.

[51]  Peter B. Jones,et al.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. , 2015, The lancet. Psychiatry.

[52]  E. Severance,et al.  IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia , 2015, Brain, Behavior, and Immunity.

[53]  Hartwig Wolburg,et al.  Transmembrane proteins of the tight junctions at the blood-brain barrier: structural and functional aspects. , 2015, Seminars in cell & developmental biology.

[54]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[55]  R. Thorne,et al.  Probing the extracellular diffusion of antibodies in brain using in vivo integrative optical imaging and ex vivo fluorescence imaging. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[56]  S. Hladky,et al.  Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence , 2014, Fluids and Barriers of the CNS.

[57]  Peter B. Jones,et al.  Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series , 2014, Schizophrenia Research.

[58]  Ilan Shelef,et al.  Blood-brain barrier imaging in human neuropathologies. , 2014, Archives of medical research.

[59]  Hany M. Elsheikha,et al.  Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood–brain barrier , 2014, Brain Research.

[60]  G. Spalletta,et al.  Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood–brain barrier integrity , 2014, Molecular Psychiatry.

[61]  S. Bonassi,et al.  Systematic Review and Meta-Analysis of Circulating S100B Blood Levels in Schizophrenia , 2014, PloS one.

[62]  Tyrone D. Cannon,et al.  Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project , 2014, Schizophrenia bulletin.

[63]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[64]  David J Petron,et al.  Blood-based biomarkers for traumatic brain injury: evaluation of research approaches, available methods and potential utility from the clinician and clinical laboratory perspectives. , 2014, Clinical biochemistry.

[65]  H. Ehrenreich,et al.  Apolipoprotein E4 carrier status plus circulating anti-NMDAR1 autoantibodies: association with schizoaffective disorder , 2014, Molecular Psychiatry.

[66]  T. Bolwig,et al.  Electroconvulsive therapy, hypertensive surge, blood-brain barrier breach, and amnesia: exploring the evidence for a connection. , 2014, The journal of ECT.

[67]  E. Smeraldi,et al.  Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia , 2014, European Psychiatry.

[68]  Thomas Brinker,et al.  A new look at cerebrospinal fluid circulation , 2014, Fluids and Barriers of the CNS.

[69]  R. Murray,et al.  Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function , 2014, Biological Psychiatry.

[70]  D. Matsuzawa,et al.  A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia , 2014, Psychiatry Research.

[71]  P. Mortensen,et al.  The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis , 2014, Biological Psychiatry.

[72]  P. Harrison,et al.  Do Neuronal Autoantibodies Cause Psychosis? A Neuroimmunological Perspective , 2014, Biological Psychiatry.

[73]  Fariba Mashayekhi Mazar,et al.  Polymorphism of the CLDN5 gene and Schizophrenia in an Iranian Population , 2014, Iranian journal of public health.

[74]  A. David,et al.  Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis‡ , 2013, Psychological Medicine.

[75]  R. Ransohoff,et al.  Development, maintenance and disruption of the blood-brain barrier , 2013, Nature Medicine.

[76]  K. Hashimoto,et al.  Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine , 2013, Neuroscience Letters.

[77]  D. Janigro,et al.  Intracellular and circulating neuronal antinuclear antibodies in human epilepsy , 2013, Neurobiology of Disease.

[78]  M. Webster,et al.  Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia , 2013, Translational Psychiatry.

[79]  J. Dalmau,et al.  Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. , 2013, JAMA neurology.

[80]  D. Janigro,et al.  Does Systemic Inflammation Play a Role in Pediatric Psychosis? , 2013, Clinical schizophrenia & related psychoses.

[81]  J. Zhong,et al.  Consequences of Repeated Blood-Brain Barrier Disruption in Football Players , 2013, PloS one.

[82]  E. D. Lange.  Utility of CSF in translational neuroscience , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[83]  R. Thorne,et al.  Diffusion of macromolecules in the brain: implications for drug delivery. , 2013, Molecular pharmaceutics.

[84]  K. Kendler,et al.  Expanding the domain of the understandable in psychiatric illness: an updating of the Jasperian framework of explanation and understanding , 2013, Psychological Medicine.

[85]  E. B. Rognli,et al.  Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? , 2012, BMC Psychiatry.

[86]  R. Murray,et al.  The Myth of Schizophrenia as a Progressive Brain Disease , 2012, Schizophrenia bulletin.

[87]  B. Bogerts,et al.  Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: Further evidence for disease course-related immune alterations? , 2012, Brain, Behavior, and Immunity.

[88]  G. E. Vates,et al.  A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β , 2012, Science Translational Medicine.

[89]  M. de Curtis,et al.  Seizure‐induced brain‐borne inflammation sustains seizure recurrence and blood–brain barrier damage , 2012, Annals of neurology.

[90]  P. Mortensen,et al.  Autoimmune diseases and infections as risk factors for schizophrenia , 2012, Annals of the New York Academy of Sciences.

[91]  A. Friedman,et al.  Pathophysiology of the Neurovascular Unit: Disease Cause or Consequence? , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[92]  Stuart B. Hooper,et al.  Initiation of Resuscitation with High Tidal Volumes Causes Cerebral Hemodynamic Disturbance, Brain Inflammation and Injury in Preterm Lambs , 2012, PloS one.

[93]  G. Lewis,et al.  Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies , 2012, Psychological Medicine.

[94]  A. Sinclair,et al.  Cerebrospinal fluid and lumbar puncture: a practical review , 2012, Journal of Neurology.

[95]  Abraham Weizman,et al.  Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice , 2011, Translational Psychiatry.

[96]  M. Cannon,et al.  Is traumatic brain injury a risk factor for schizophrenia? A meta-analysis of case-controlled population-based studies. , 2011, Schizophrenia bulletin.

[97]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[98]  S. Claes,et al.  Relationship between P-glycoprotein and second-generation antipsychotics. , 2011, Pharmacogenomics.

[99]  B. Engelhardt,et al.  Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle , 2011, Fluids and Barriers of the CNS.

[100]  Alessandra Bertoldo,et al.  The impact of schizophrenia on frontal perfusion parameters: a DSC-MRI study , 2011, Journal of Neural Transmission.

[101]  M. Valis,et al.  Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study , 2011, BMC psychiatry.

[102]  P. Mazzone,et al.  Pathophysiological Impact of Cigarette Smoke Exposure on the Cerebrovascular System with a Focus on the Blood-brain Barrier: Expanding the Awareness of Smoking Toxicity in an Underappreciated Area , 2010, International journal of environmental research and public health.

[103]  M. Cipolla,et al.  Plasma From Preeclamptic Women Increases Blood-Brain Barrier Permeability: Role of Vascular Endothelial Growth Factor Signaling , 2010, Hypertension.

[104]  J. A. Boer,et al.  Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [11C]verapamil as a probe for P-glycoprotein function , 2010, Psychiatry Research: Neuroimaging.

[105]  D. Fuchs,et al.  Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. , 2010, Journal of psychiatric research.

[106]  Edward T. Bullmore,et al.  Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections , 2010, PloS one.

[107]  B. Bogerts,et al.  S100B serum levels are closely correlated with body mass index: An important caveat in neuropsychiatric research , 2010, Psychoneuroendocrinology.

[108]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[109]  H. Stolp,et al.  Review: Role of developmental inflammation and blood–brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases , 2009, Neuropathology and applied neurobiology.

[110]  S. Moochhala,et al.  Involvement of ROS in BBB dysfunction , 2009, Free radical research.

[111]  G. Ju,et al.  A Weak Association of the CLDN5 Locus with Schizophrenia in Chinese Case-control Samples , 2009, European Psychiatry.

[112]  T. Giger,et al.  The Cerebral Microvasculature in Schizophrenia: A Laser Capture Microdissection Study , 2008, PloS one.

[113]  R. Balice-Gordon,et al.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies , 2008, The Lancet Neurology.

[114]  H. Adèr,et al.  Psychosis in epilepsy patients and other chronic medically ill patients and the role of cerebral pathology in the onset of psychosis: A clinical epidemiological study , 2008, Seizure.

[115]  R. Yolken,et al.  Are some cases of psychosis caused by microbial agents? A review of the evidence , 2008, Molecular Psychiatry.

[116]  C. Hiemke,et al.  Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice , 2008, Behavioural Brain Research.

[117]  N. Uranova,et al.  Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[118]  C. Iadecola,et al.  Glial regulation of the cerebral microvasculature , 2007, Nature Neuroscience.

[119]  Michele Tansella,et al.  Assessment of cerebral blood volume in schizophrenia: A magnetic resonance imaging study. , 2007, Journal of psychiatric research.

[120]  P. Parzer,et al.  Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia , 2007, Psychological Medicine.

[121]  David S. Miller,et al.  Tumor Necrosis Factor α and Endothelin-1 Increase P-Glycoprotein Expression and Transport Activity at the Blood-Brain Barrier , 2007, Molecular Pharmacology.

[122]  Y. Minabe,et al.  Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia , 2007, Schizophrenia Research.

[123]  Craig Morgan,et al.  Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma--a critical review. , 2006, Schizophrenia bulletin.

[124]  C. Brosnan,et al.  IL-1β Regulates Blood-Brain Barrier Permeability via Reactivation of the Hypoxia-Angiogenesis Program1 , 2006, The Journal of Immunology.

[125]  B. Volpe,et al.  Immunity and behavior: antibodies alter emotion. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[126]  J. Kleinman,et al.  Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia , 2005, Neuroscience.

[127]  K. Linnet,et al.  P‐glycoprotein interaction with risperidone and 9‐OH‐risperidone studied in vitro, in knock‐out mice and in drug–drug interaction experiments , 2005, Human psychopharmacology.

[128]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[129]  Yan Shen,et al.  Further study of a genetic association between the CLDN5 locus and schizophrenia , 2005, Schizophrenia Research.

[130]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[131]  J. Donovan,et al.  The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. , 2004, The international journal of neuropsychopharmacology.

[132]  Y. Shen,et al.  The CLDN5 locus may be involved in the vulnerability to schizophrenia , 2004, European Psychiatry.

[133]  N. Joan Abbott,et al.  Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology , 2004, Neurochemistry International.

[134]  J. Rothstein,et al.  Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. , 2003, Virology.

[135]  S. Tsukita,et al.  Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice , 2003, The Journal of cell biology.

[136]  S. Kornfeld,et al.  Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.

[137]  N. Bodor,et al.  Brain-Targeted Drug Delivery , 2003 .

[138]  T. Dinan,et al.  Elevated expression of integrin αIIb βIIIa in drug-naïve, first-episode schizophrenic patients , 2002, Biological Psychiatry.

[139]  Peter B. Jones,et al.  Obstetric complications and schizophrenia: historical and meta-analytic review. , 2002, The American journal of psychiatry.

[140]  T. Davis,et al.  Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. , 2002, American journal of physiology. Heart and circulatory physiology.

[141]  R. Yolken,et al.  Immunohistochemical Localization of Phosphorylated Glial Fibrillary Acidic Protein in the Prefrontal Cortex and Hippocampus from Patients with Schizophrenia, Bipolar Disorder, and Depression , 2001, Brain, Behavior, and Immunity.

[142]  R. Rimón,et al.  Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia , 2001, Schizophrenia Research.

[143]  S. Caccia.  Biotransformation of Post-Clozapine Antipsychotics , 2000 .

[144]  M. Schwarz,et al.  Decreased levels of soluble intercellular adhesion Molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients , 2000, Biological Psychiatry.

[145]  J. Viña,et al.  Na+-dependent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain Barrier , 1999, The Journal of Biological Chemistry.

[146]  R. Rimón,et al.  Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. , 1999, The American journal of psychiatry.

[147]  M. Owen,et al.  High rates of schizophrenia in adults with velo-cardio-facial syndrome (VCFS) , 1999, Schizophrenia Research.

[148]  W. Schaper,et al.  Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. , 1999, American journal of physiology. Cell physiology.

[149]  M. Schwarz,et al.  Blood–cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia , 1998, Neuroscience Letters.

[150]  M. Ackenheil,et al.  Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ γ/δ+) in unmedicated schizophrenic patients: relation to impairment of the blood–brain barrier and HLA-DPA*02011 , 1998, Schizophrenia Research.

[151]  A. David,et al.  Premorbid adjustment and personality in people with schizophrenia† , 1998, British Journal of Psychiatry.

[152]  R. Kucherlapati,et al.  Identification, characterization, and precise mapping of a human gene encoding a novel membrane-spanning protein from the 22q11 region deleted in velo-cardio-facial syndrome. , 1997, Genomics.

[153]  R. Sandyk.  Choroid plexus calcification as a possible marker of hallucinations in schizophrenia. , 1993, The International journal of neuroscience.

[154]  J. Lieberman,et al.  Gadolinium-DTPA enhanced gradient echo magnetic resonance scans in first episode of psychosis and chronic schizophrenic patients , 1991, Psychiatry Research: Neuroimaging.

[155]  S. Kay,et al.  Calcification of the choroid plexus as a marker of depression in schizophrenia , 1990, Schizophrenia Research.

[156]  O. R. Blaumanis,et al.  Evidence for a ‘Paravascular’ fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space , 1985, Brain Research.

[157]  C. Patlak,et al.  Drainage of interstitial fluid from different regions of rat brain. , 1984, The American journal of physiology.

[158]  C. Patlak,et al.  Efflux of radiolabeled polyethylene glycols and albumin from rat brain. , 1981, The American journal of physiology.

[159]  H. Cserr,et al.  Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit. , 1981, The American journal of physiology.

[160]  R. Ransohoff,et al.  The blood-brain barrier. , 2016, Handbook of clinical neurology.

[161]  H. Tanila,et al.  Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. , 2015, Journal of Alzheimer's disease : JAD.

[162]  S. Najjar,et al.  Neuroinflammation and white matter pathology in schizophrenia: systematic review , 2015, Schizophrenia Research.

[163]  R. Daneman,et al.  The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.

[164]  J. Hammond,et al.  Postmortem Brain: An Underutilized Substrate for Studying Severe Mental Illness , 2014, Neuropsychopharmacology.

[165]  N. Abbott.  Anatomy and Physiology of the Blood–Brain Barriers , 2014 .

[166]  D. Begley,et al.  Transcytosis of macromolecules at the blood-brain barrier. , 2014, Advances in pharmacology.

[167]  F. Verhey,et al.  Amyloid-β interacts with blood-brain barrier function in dementia: a systematic review. , 2013, Journal of Alzheimer's disease : JAD.

[168]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.